Clinical Trial Results:
            A Phase III double-blind, double-dummy, placebo-controlled, 8 week fixed dose trial with pramipexole IR (Mirapex®, Mirapexin®, Pexola®, Sifrol®) 0.125 and 0.5 mg/day administered orally to investigate the efficacy and safety in patients 6-17 years of age diagnosed with Tourette Syndrome according to DSM-IV criteria
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2008-000343-33 | 
    Trial protocol  | 
        DE | 
    Global completion date  | 
        
                                    07 Aug 2009
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1 | 
    This version publication date  | 
        
                                    07 Jul 2018
                             
         | 
    
    First version publication date  | 
        
                                    07 Jul 2018
                             
         | 
    
    Other versions  | 
        v2 | 
    Summary report(s)  | 
                                Statement | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.